List of Excipients in Branded Drug LOPINAVIR AND RITONAVIR

Generic Drugs Containing LOPINAVIR AND RITONAVIR

Company	Ingredient	NDC	Excipient
Camber Pharmaceuticals Inc	lopinavir and ritonavir	31722-556	COPOVIDONE K25-31
Camber Pharmaceuticals Inc	lopinavir and ritonavir	31722-556	FERRIC OXIDE YELLOW
Camber Pharmaceuticals Inc	lopinavir and ritonavir	31722-556	HYDROXYPROPYL CELLULOSE
Camber Pharmaceuticals Inc	lopinavir and ritonavir	31722-556	HYPROMELLOSE 2910
Camber Pharmaceuticals Inc	lopinavir and ritonavir	31722-556	POLYETHYLENE GLYCOL 3350

What are the Most Frequently-Used Excipients in LOPINAVIR AND RITONAVIR?

# Of NDCs	Excipient
1	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
3	COPOVIDONE
1	COPOVIDONE K25-31
4	FERRIC OXIDE YELLOW
3	HYDROXYPROPYL CELLULOSE

Lopinavir and Ritonavir Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

Lopinavir/ritonavir is a mature fixed-dose HIV protease inhibitor combination with limited branded growth but continuing formulation, generic, pediatric, and emerging-market opportunities. The strongest commercial positions are in taste-masked oral liquids, low-alcohol pediatric products, heat-stable tablets, excipient supply, and manufacturing platforms that reduce food and storage constraints. The principal risks are declining first-line use, extensive historical patent disclosure, generic price pressure, and limited prospects for new high-income-market indications.

What is the commercial status of lopinavir/ritonavir?

Lopinavir/ritonavir is marketed primarily as Kaletra in the United States and Aluvia in many international markets. Abbott Laboratories developed the product, and AbbVie became the relevant branded company after the Abbott pharmaceutical separation.

The combination uses ritonavir as a pharmacokinetic booster. Ritonavir inhibits CYP3A-mediated metabolism of lopinavir, increasing lopinavir exposure and permitting a lower effective lopinavir dose.

Product	Active ingredients	Main dosage forms	Original commercial role
Kaletra	Lopinavir/ritonavir	100/25 mg tablets, 200/50 mg tablets, oral solution	HIV-1 treatment with other antiretrovirals
Aluvia	Lopinavir/ritonavir	Tablets and oral solution in international markets	HIV-1 treatment, particularly in resource-limited settings
Norvir	Ritonavir	Tablets, capsules, oral solution	Booster and, historically, standalone protease inhibitor

The U.S. Food and Drug Administration approved Kaletra tablets in 2005 after earlier approval of the oral solution. The product has been used in adults and children, but its role has narrowed as integrase inhibitor-based regimens have become preferred for most patients. The U.S. Department of Health and Human Services guidelines identify dolutegravir- and bictegravir-based regimens as preferred options for most adults, while lopinavir/ritonavir remains relevant in selected circumstances and pediatric treatment settings.[1]

The COVID-19 development opportunity did not materialize. The RECOVERY trial found no clinical benefit from lopinavir/ritonavir in hospitalized patients, and the World Health Organization recommended against its use for hospitalized COVID-19 patients.[2,3]

What excipients are used in lopinavir/ritonavir products?

The tablet and oral-solution platforms use materially different excipient strategies.

Tablet excipients

The tablet is a solid dispersion-type formulation designed to improve lopinavir and ritonavir dissolution and reduce dependence on food intake. U.S. labeling identifies excipients including copovidone, sorbitan laurate, colloidal silicon dioxide, sodium stearyl fumarate, hypromellose, titanium dioxide, talc, polyethylene glycol, and polysorbate 80.[4]

Excipient or excipient class	Formulation function	Commercial relevance
Copovidone	Polymer matrix and solubilization support	Potential source of bioequivalence and process differentiation
Sorbitan laurate	Surfactant and wetting aid	Helps disperse poorly water-soluble actives
Colloidal silicon dioxide	Glidant and adsorption aid	Supports powder flow and process control
Sodium stearyl fumarate	Lubricant	Alternative to conventional magnesium stearate in sensitive formulations
Hypromellose	Film former and polymeric matrix component	Supports coating and physical stability
Polyethylene glycol	Plasticizer and coating component	Controls film flexibility and appearance
Polysorbate 80	Surfactant	Supports wetting and dispersion
Talc and titanium dioxide	Coating and opacity	Relevant to tablet appearance and light protection

The commercial lesson is that excipient selection is linked to the product's biopharmaceutical design. Lopinavir and ritonavir are poorly water-soluble compounds, and a conventional immediate-release tablet may not reproduce the reference product's dissolution, exposure, or food effect. A generic developer therefore needs more than a simple excipient substitution strategy.

Oral-solution excipients

The oral solution has a more complex tolerability and supply profile. Labelled components include ethanol, high-fructose corn syrup, propylene glycol, glycerin, polyoxyl 35 castor oil, acesulfame potassium, saccharin sodium, citric acid, menthol, peppermint oil, caramel, and other flavoring or pH-control components.[4]

These excipients create several constraints:

• Ethanol and propylene glycol complicate pediatric use and regulatory review.
• High-fructose corn syrup creates concerns for diabetic patients, metabolic disorders, and certain markets.
• Polyoxyl 35 castor oil can affect gastrointestinal tolerability.
• Menthol and peppermint flavoring do not eliminate the bitter taste burden.
• The solution requires careful control of density, viscosity, preservative performance, and active uniformity.
• Alcohol content can create transport, labeling, and cultural-market barriers.

The oral solution remains clinically useful when children cannot swallow tablets, but its excipient profile creates a clear opening for a lower-alcohol, lower-sugar, better-tasting product.

What formulation patents protect lopinavir/ritonavir?

The principal historical protection for lopinavir/ritonavir covered the combination, pharmaceutical compositions, and processes associated with the product. Important historical U.S. patents included:

Patent	Historical subject matter	Commercial significance
U.S. Patent No. 5,484,801	Protease inhibitor chemistry and related compositions	Early compound-level protection associated with the HIV protease inhibitor portfolio
U.S. Patent No. 5,541,206	Ritonavir-related pharmaceutical protection	Historical protection for ritonavir
U.S. Patent No. 5,914,332	Lopinavir-related pharmaceutical protection	Historical protection associated with lopinavir
U.S. Patent No. 6,555,466	Lopinavir/ritonavir pharmaceutical composition	Key historical combination and formulation protection

Patent terms for these early U.S. patents have expired or reached the end of their statutory life. The commercial barrier is therefore less likely to be a single surviving compound patent and more likely to involve regulatory requirements, manufacturing capability, bioequivalence, supplier qualification, and market access.

Patent status differs by jurisdiction. Historical national patents, supplementary protection certificates, pediatric extensions, manufacturing claims, and regulatory exclusivities must be assessed country by country. A formulation developer should not assume that expiration of the original U.S. patent family eliminates all constraints in Europe, emerging markets, or procurement jurisdictions.

When did lopinavir/ritonavir lose exclusivity?

The core U.S. exclusivity period ended years ago. Kaletra was approved in 2000, and its principal early patent protection was based on applications filed in the 1990s. Any pediatric extension associated with the product was limited and did not create a long-term commercial barrier.

Event	Approximate timing	Effect
Original Kaletra U.S. approval	2000	Established the branded fixed-dose combination
Tablet approval	2005	Expanded the preferred solid dosage form
Major historical compound and combination patents	2010s	Expired or reached statutory endpoints
International generic competition	2010s onward	Increased price pressure
COVID-19 repurposing studies	2020-2021	Did not produce a new indication
Current commercial position	2020s	Mature, declining high-income-market product with continuing access-market demand

The product should be treated as an off-patent or substantially mature platform, subject to jurisdiction-specific Orange Book, national register, and regulatory-exclusivity review.

What is the Orange Book status of Kaletra?

Kaletra has been listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, under AbbVie's lopinavir/ritonavir products. The relevant listings concern the 100/25 mg and 200/50 mg tablets and the oral solution.

The practical issue for a generic developer is not only whether a patent is listed. It is whether the reference product's formulation can be matched sufficiently to support an Abbreviated New Drug Application. A Paragraph IV certification may be relevant where an applicant identifies an unexpired listed patent, but the historical Kaletra patent estate is substantially aged.

What Paragraph IV challenges affect lopinavir/ritonavir?

Paragraph IV risk is comparatively lower than for a newly launched small molecule because the major composition and combination patents are old. Potential challenges have centered on:

• Tablet composition and solid-dispersion technology.
• Process claims.
• Oral-solution formulation claims.
• Method-of-use claims for HIV treatment.
• Later patents covering manufacturing or specific excipient arrangements.

A Paragraph IV filing could still trigger litigation if a listed patent remains active in a particular jurisdiction. The commercial value of such litigation is limited by declining branded sales and the availability of alternative antiretroviral regimens.

What excipient strategies can improve lopinavir/ritonavir?

The most attractive strategy is to preserve exposure while improving tolerability, storage, administration, and manufacturing economics.

1. Low-alcohol pediatric oral solution

A reformulated solution could replace or reduce ethanol and propylene glycol while retaining adequate solubility and dose uniformity. Candidate approaches include:

• Cosolvent reduction through surfactant optimization.
• Cyclodextrin-based solubilization.
• Polymeric solubilizers.
• Lipid-based self-emulsifying systems.
• Improved flavor masking with less peppermint and menthol intensity.
• Lower-sugar or sugar-free vehicles.
• Preservative systems compatible with pediatric use.

The key regulatory requirement would be a clinically acceptable exposure profile relative to the reference solution or tablet. A lower excipient burden would have limited value if it materially changed absorption.

2. Taste-masked pediatric granules or multiparticulates

Taste-masked granules could fill the gap between liquid and tablet products. Possible platforms include:

• Polymer-coated microparticles.
• Ion-exchange resin complexes.
• Lipid-coated granules.
• Sprinkle capsules.
• Orodispersible granules administered with soft food.
• Sachets for reconstitution.

This format could reduce alcohol exposure and improve portability. It also could lower dosing errors compared with a viscous oral solution. Taste masking is technically difficult because both lopinavir and ritonavir have strong bitterness and because the administered dose is relatively large.

3. Heat-stable solid dosage forms

Heat-stable tablets remain commercially important in tropical and low-resource markets. Excipient programs should prioritize:

• Low moisture uptake.
• Resistance to high-temperature storage.
• Robust packaging compatibility.
• Reduced dependence on refrigerated distribution.
• Stable dissolution after accelerated aging.
• Use of globally available excipients.

Packaging is part of the formulation strategy. High-barrier blister materials, desiccant systems, and moisture-resistant coatings can produce a larger stability benefit than a small change in tablet excipients.

4. Smaller and lower-cost tablets

The standard 200/50 mg tablet is relatively large. Opportunities include:

• Higher drug loading.
• Bilayer or multilayer compression.
• Optimized granulation.
• Reduced coating weight.
• Mini-tablets for children.
• Lower-cost excipient substitutions supported by comparative dissolution data.

The main obstacle is maintaining the reference product's performance. Excipients that reduce tablet size may also alter wetting, supersaturation, precipitation, and food effect.

5. Fixed-dose combination expansion

Lopinavir/ritonavir could be incorporated into broader antiretroviral combinations where permitted by treatment guidelines and procurement requirements. Commercially relevant formats include pediatric fixed-dose combinations and co-packaged regimens.

Combination expansion faces clinical and regulatory limits. Current treatment guidelines have shifted toward integrase inhibitors, and a new combination must demonstrate a clear access, tolerability, or supply advantage.

What manufacturing and intellectual-property barriers exist?

The primary technical barrier is dissolution control. Lopinavir and ritonavir have low aqueous solubility, and the reference tablet's performance depends on a coordinated excipient system rather than a single enabling ingredient.

Manufacturing risks include:

• Variation in polymer molecular weight.
• Surfactant source and impurity profile.
• Powder flow and compression behavior.
• Coating uniformity.
• Residual solvent control.
• Active segregation during blending.
• Changes in particle size or solid state.
• Dissolution drift during stability studies.

Supplier qualification is material. A manufacturer that relies on one grade of copovidone, one surfactant supplier, or one coating system may face avoidable supply disruption. Dual sourcing should be built into development before pivotal bioequivalence batches.

IP risk is concentrated in later formulation claims, process patents, trade secrets, and know-how. Even where patent claims have expired, the reference product's development history can make formulation reverse engineering difficult. A new excipient combination may also create its own patent position if it produces a clinically relevant improvement, such as lower alcohol exposure or improved pediatric adherence.

Which companies are challenging or competing with Kaletra?

Competition comes from three groups:

1. Generic antiretroviral manufacturers.
2. Public-health suppliers serving Global Fund, PEPFAR, UNICEF, and national procurement programs.
3. Manufacturers of newer antiretroviral regimens that displace lopinavir/ritonavir clinically.

Generic companies in the HIV market have included Cipla, Mylan/Viatris, Hetero, Laurus Labs, Aurobindo, and other regionally approved manufacturers. The relevant competitive advantage is often procurement eligibility, World Health Organization prequalification, manufacturing scale, and price rather than proprietary formulation technology.

The strongest clinical competitors are dolutegravir-based and bictegravir-based regimens. These products have better tolerability, simpler dosing, and stronger guideline positioning in many markets.[1]

What licensing deals and access partnerships matter?

Lopinavir/ritonavir has been associated with public-health licensing and access arrangements rather than high-value commercial licensing in developed markets. Licensing and procurement opportunities have included:

• Voluntary licenses for generic production.
• Technology transfer for heat-stable tablets.
• WHO prequalification pathways.
• Pooled procurement.
• Pediatric HIV access programs.
• National tender agreements.
• Humanitarian supply arrangements.

The commercial value of a license depends on geographic scope, regulatory status, minimum purchase commitments, technology-transfer obligations, and whether the license covers only active pharmaceutical ingredients or also finished-dose formulation and manufacturing know-how.

What is the litigation status for lopinavir/ritonavir?

The major litigation risk is historical patent litigation involving compound, combination, and formulation protection. Current commercial litigation risk is lower than during the product's launch period because core U.S. patent terms have expired and the product is mature.

Potential disputes remain possible over:

• Orange Book patent certifications.
• Formulation patents in individual jurisdictions.
• Patent-term extensions.
• Data exclusivity or regulatory exclusivity.
• Procurement-related trademark and trade dress issues.
• Antitrust claims involving delayed generic entry.
• Manufacturing-process patents.

No litigation position should be inferred solely from the existence of a historical patent family. Litigation exposure depends on live claims, jurisdiction, listed-patent status, filing dates, and whether the proposed generic design practices the asserted claims.

What is the revenue exposure and commercial opportunity?

Branded lopinavir/ritonavir revenue is structurally exposed to therapeutic substitution. HIV treatment has shifted toward once-daily integrase inhibitor regimens, reducing demand for boosted protease inhibitors in high-income markets.

Commercial opportunity remains in five areas:

Opportunity	Market logic	Main risk
Pediatric oral solution	Children may be unable to swallow tablets	Taste, alcohol, and sugar burden
Low-cost heat-stable tablets	Continued demand in low- and middle-income countries	Tender price compression
Excipient supply	Repeat demand from multiple generic manufacturers	Commoditization
Improved multiparticulates	Better administration and portability	Bioequivalence complexity
Regional manufacturing	Local supply resilience and procurement preference	Limited margins and regulatory costs

A new formulation is more likely to succeed through access-market differentiation than through premium pricing. The best target is a product that lowers total treatment cost, reduces cold-chain or storage requirements, and solves a specific pediatric administration problem.

How strong is the patent estate for lopinavir/ritonavir?

The original estate was commercially strong during the launch period but is now weak as a blocking platform. Its residual value lies in:

• Historical formulation know-how.
• Manufacturing process control.
• Regulatory documentation.
• Brand recognition in HIV procurement.
• Potentially active jurisdiction-specific secondary patents.
• Trade secrets associated with solid dispersion and scale-up.

For a new entrant, regulatory execution and manufacturing reliability are more important than freedom from a broad foundational patent. For an excipient supplier, the opportunity is to create differentiated grades or co-processed systems that improve dissolution, compressibility, taste masking, or stability without relying on an expired claim set.

What generic launch scenarios exist?

Three launch scenarios are commercially credible.

Scenario 1: Conventional tablet generic

The applicant matches the 200/50 mg reference tablet using a comparable polymer-surfactant system. This is the lowest differentiation pathway and faces severe price competition.

Scenario 2: Pediatric taste-masked product

The applicant develops granules, mini-tablets, or a low-alcohol solution. This offers greater differentiation and may support procurement contracts, but it requires stronger clinical and human-factors evidence.

Scenario 3: Regional access platform

The applicant combines WHO-aligned regulatory status, local manufacturing, high-temperature stability, and low-cost packaging. This can be commercially viable even without premium pricing if the product qualifies for major tenders.

Key Takeaways

• Lopinavir/ritonavir is a mature, largely off-patent HIV product with declining branded demand in high-income markets.
• The tablet depends on a sophisticated excipient system for dissolution and exposure control.
• The oral solution's ethanol, propylene glycol, high-fructose corn syrup, and strong flavor profile create the clearest reformulation opportunity.
• Pediatric granules, taste-masked multiparticulates, and low-alcohol liquids offer more differentiation than another conventional tablet.
• Heat stability, packaging, and global excipient sourcing are central to emerging-market competitiveness.
• Historical patents, including U.S. Patent Nos. 5,484,801, 5,541,206, 5,914,332, and 6,555,466, no longer provide the same blocking power as during product launch.
• Generic entry risk is high, but the best opportunities are access-driven and formulation-specific.
• New clinical use in COVID-19 did not create a commercial market after negative randomized-trial results.
• The strongest competing regimens are dolutegravir- and bictegravir-based products.
• Excipient suppliers can capture value through differentiated polymer, surfactant, taste-masking, and stability platforms rather than commodity materials alone.

FAQs

Can lopinavir/ritonavir be reformulated without ethanol?

Yes. A lower-alcohol or alcohol-free oral formulation is technically possible, but it must maintain solubility, dose uniformity, microbiological quality, palatability, and bioequivalence.

Which excipient is most important for lopinavir/ritonavir tablet performance?

Copovidone is a key formulation component because the tablet relies on polymer-assisted dispersion and dissolution. Its grade, molecular weight, moisture profile, and interaction with surfactants can affect performance.

Is a lopinavir/ritonavir pediatric product commercially attractive?

It can be attractive in markets with continued pediatric HIV demand, particularly if it reduces alcohol, improves taste, and remains stable under tropical conditions. Guideline displacement by newer regimens limits the addressable market.

Does ritonavir create separate formulation opportunities?

Yes. Ritonavir's strong CYP3A inhibition supports its use as a booster in other antiviral regimens. However, the commercial opportunity is driven by the newer active ingredient being boosted, not by ritonavir alone.

Are excipient patents likely to block a lopinavir/ritonavir generic?

Broad foundational blocking patents are less likely to be the main obstacle today. Later formulation or process patents may remain relevant in specific jurisdictions, but bioequivalence, manufacturing know-how, and regulatory execution generally present the larger commercial barriers.

References

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services.

2. Horby, P. W., Mafham, M., Bell, J. L., Linsell, L., Staplin, N., Emberson, J. R., et al. (2020). Lopinavir-ritonavir in patients admitted to hospital with COVID-19: A randomised controlled, open-label, platform trial. The Lancet, 396(10259), 1345-1352.

3. World Health Organization. (2021). Therapeutics and COVID-19: Living guideline. World Health Organization.

4. U.S. Food and Drug Administration. (2023). Kaletra (lopinavir/ritonavir) prescribing information. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

6. United States Patent and Trademark Office. (Various years). U.S. Patent Nos. 5,484,801; 5,541,206; 5,914,332; and 6,555,466. U.S. Department of Commerce.